The Risk of COVID-19 and Its Outcomes in Korean Patients With Gout: A Multicenter, Retrospective, Observational Study

Overview

Journal J Korean Med Sci

Specialty General Medicine

Date 2024 Jan 30

PMID 38288538

Authors

Min Jung Kim

Borim Ryu

Eun-Gee Park

Siyeon Yi

Kwangsoo Kim

Jun Won Park

Kichul Shin

Affiliations

Soon will be listed here.

Abstract

This retrospective cohort study aimed to compare coronavirus disease 2019 (COVID-19)-related clinical outcomes between patients with and without gout. Electronic health record-based data from two centers (Seoul National University Hospital [SNUH] and Boramae Medical Center [BMC]), from January 2021 to April 2022, were mapped to a common data model. Patients with and without gout were matched using a large-scale propensity-score algorithm based on population-level estimation methods. At the SNUH, the risk for COVID-19 diagnosis was not significantly different between patients with and without gout (hazard ratio [HR], 1.07; 95% confidence interval [CI], 0.59-1.84). Within 30 days after COVID-19 diagnosis, no significant difference was observed in terms of hospitalization (HR, 0.57; 95% CI, 0.03-3.90), severe outcomes (HR, 2.90; 95% CI, 0.54-13.71), or mortality (HR, 1.35; 95% CI, 0.06-16.24). Similar results were obtained from the BMC database, suggesting that gout does not increase the risk for COVID-19 diagnosis or severe outcomes.

References

Choi H, McCormick N, Yokose C . Excess comorbidities in gout: the causal paradigm and pleiotropic approaches to care. Nat Rev Rheumatol. 2021; 18(2):97-111. DOI: 10.1038/s41584-021-00725-9. View

Moraliyska R, Georgiev T, Bogdanova-Petrova S, Shivacheva T . Adoption rates of recommended vaccines and influencing factors among patients with inflammatory arthritis: a patient survey. Rheumatol Int. 2023; 44(1):165-172. DOI: 10.1007/s00296-023-05476-2. View

Tian Y, Schuemie M, Suchard M . Evaluating large-scale propensity score performance through real-world and synthetic data experiments. Int J Epidemiol. 2018; 47(6):2005-2014. PMC: 6280944. DOI: 10.1093/ije/dyy120. View

Tai V, Robinson P, Dalbeth N . Gout and the COVID-19 pandemic. Curr Opin Rheumatol. 2021; 34(2):111-117. DOI: 10.1097/BOR.0000000000000860. View

Crisan T, Cleophas M, Oosting M, Lemmers H, Toenhake-Dijkstra H, Netea M . Soluble uric acid primes TLR-induced proinflammatory cytokine production by human primary cells via inhibition of IL-1Ra. Ann Rheum Dis. 2015; 75(4):755-62. DOI: 10.1136/annrheumdis-2014-206564. View

Xie D, Choi H, Dalbeth N, Wallace Z, Sparks J, Lu N . Gout and Excess Risk of Severe SARS-CoV-2 Infection Among Vaccinated Individuals: A General Population Study. Arthritis Rheumatol. 2022; 75(1):122-132. PMC: 9537980. DOI: 10.1002/art.42339. View

Jatuworapruk K, Montgomery A, Gianfrancesco M, Conway R, Durcan L, Graef E . Characteristics and Outcomes of People With Gout Hospitalized Due to COVID-19: Data From the COVID-19 Global Rheumatology Alliance Physician-Reported Registry. ACR Open Rheumatol. 2022; 4(11):948-953. PMC: 9539246. DOI: 10.1002/acr2.11495. View

Yasmin F, Najeeb H, Moeed A, Naeem U, Asghar M, Chughtai N . COVID-19 Vaccine Hesitancy in the United States: A Systematic Review. Front Public Health. 2021; 9:770985. PMC: 8650625. DOI: 10.3389/fpubh.2021.770985. View

Peng H, Wu X, Xiong S, Li C, Zhong R, He J . Gout and susceptibility and severity of COVID-19: A bidirectional Mendelian randomization analysis. J Infect. 2022; 85(3):e59-e61. PMC: 9212781. DOI: 10.1016/j.jinf.2022.05.042. View

10.

Shin Y, Shin J, Moon S, Jin H, Kim S, Yang J . Autoimmune inflammatory rheumatic diseases and COVID-19 outcomes in South Korea: a nationwide cohort study. Lancet Rheumatol. 2021; 3(10):e698-e706. PMC: 8213376. DOI: 10.1016/S2665-9913(21)00151-X. View

11.

Tabatabai M, Juarez P, Matthews-Juarez P, Wilus D, Ramesh A, Alcendor D . An Analysis of COVID-19 Mortality During the Dominancy of Alpha, Delta, and Omicron in the USA. J Prim Care Community Health. 2023; 14:21501319231170164. PMC: 10125879. DOI: 10.1177/21501319231170164. View

12.

Conway R, Nikiphorou E, Demetriou C, Low C, Leamy K, Ryan J . Temporal trends in COVID-19 outcomes in people with rheumatic diseases in Ireland: data from the COVID-19 Global Rheumatology Alliance registry. Rheumatology (Oxford). 2022; 61(SI2):SI151-SI156. PMC: 8992296. DOI: 10.1093/rheumatology/keac142. View

13.

Topless R, Gaffo A, Stamp L, Robinson P, Dalbeth N, Merriman T . Gout and the risk of COVID-19 diagnosis and death in the UK Biobank: a population-based study. Lancet Rheumatol. 2022; 4(4):e274-e281. PMC: 8798088. DOI: 10.1016/S2665-9913(21)00401-X. View

14.

Roddy E, Doherty M . Epidemiology of gout. Arthritis Res Ther. 2011; 12(6):223. PMC: 3046529. DOI: 10.1186/ar3199. View

15.

Tanaka T, Milaneschi Y, Zhang Y, Becker K, Zukley L, Ferrucci L . A double blind placebo controlled randomized trial of the effect of acute uric acid changes on inflammatory markers in humans: A pilot study. PLoS One. 2017; 12(8):e0181100. PMC: 5546625. DOI: 10.1371/journal.pone.0181100. View